Carnegie Capital Asset Management LLC Has $979,000 Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Carnegie Capital Asset Management LLC lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 7.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,016 shares of the medical instruments supplier’s stock after selling 344 shares during the quarter. Carnegie Capital Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $979,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. RVW Wealth LLC bought a new stake in shares of Becton, Dickinson and Company during the third quarter valued at approximately $52,000. Sapient Capital LLC bought a new stake in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $1,295,000. Vest Financial LLC grew its stake in shares of Becton, Dickinson and Company by 27.5% during the fourth quarter. Vest Financial LLC now owns 103,004 shares of the medical instruments supplier’s stock valued at $25,115,000 after purchasing an additional 22,207 shares during the last quarter. M. Kulyk & Associates LLC grew its stake in shares of Becton, Dickinson and Company by 5.1% during the third quarter. M. Kulyk & Associates LLC now owns 16,640 shares of the medical instruments supplier’s stock valued at $4,302,000 after purchasing an additional 809 shares during the last quarter. Finally, SG Americas Securities LLC grew its stake in shares of Becton, Dickinson and Company by 69.4% during the fourth quarter. SG Americas Securities LLC now owns 15,113 shares of the medical instruments supplier’s stock valued at $3,685,000 after purchasing an additional 6,190 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Price Performance

Shares of BDX stock opened at $231.01 on Wednesday. Becton, Dickinson and Company has a 52-week low of $229.85 and a 52-week high of $287.32. The stock has a market cap of $66.74 billion, a PE ratio of 54.74, a PEG ratio of 1.94 and a beta of 0.43. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. The firm’s 50 day moving average price is $240.49 and its two-hundred day moving average price is $242.72.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.39 by $0.29. The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the firm earned $2.98 earnings per share. As a group, analysts forecast that Becton, Dickinson and Company will post 12.94 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 8th were issued a $0.95 dividend. The ex-dividend date of this dividend was Thursday, March 7th. This represents a $3.80 annualized dividend and a yield of 1.64%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 90.05%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on BDX. Barclays increased their price target on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a research note on Monday, February 5th. Raymond James increased their price target on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $280.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.